Navigation Links
Une nouvelle immunothérapie anticancéreuse sur le point d'entrer en phase d'essais cliniques
Date:4/16/2013

LAWRENCEBURG, Indiana, 17 avril 2013 /PRNewswire/ -- PDS Biotechnology Corporation a présenté aujourd'hui, à l'occasion du Congrès mondial du vaccin organisé à Washington DC, une partie de ses données précliniques concernant son immunothérapie anticancéreuse PDS0101. Cette dernière a été mise au point à l'aide de Versamune™, l'innovante plate-forme vaccinale nanotechnologique de la société. PDS Biotechnology a également communiqué l'information selon laquelle sa présentation de nouveau médicament de recherche avait été autorisée par la Food and Drug Administration, ce qui ouvre la voie à une évaluation du PDS0101 chez des sujets humains.

Le PDS0101 constitue une solution immunothérapeutique de premier plan destinée au traitement des cancers et des maladies causées par une infection au papillomavirus humain : cancer du col de l'utérus, cancer de la tête et du cou, néoplasie intra-cervicale. Le Dr Frank Bedu-Addo, PDG de la société, s'est exprimé au sujet des constats très prometteurs en matière d'efficacité et de sécurité précliniques : il est désormais possible d'éradiquer les tumeurs sans avoir à subir les habituels inconvénients de sécurité rencontrés avec les technologies actuellement employées dans le domaine de l'immunothérapie. Le PDS0101 est conçu pour préparer le système immunitaire à recruter des cellules du corps qui seront chargées de repérer, cibler et tuer les cellules cancéreuses. De plus, il s'attaque à certaines cellules du système immunitaire qui empêchent ce dernier de détecter et de supprimer les cellules défectueuses. « Si les résultats précliniques d
'/>"/>

SOURCE PDS Biotechnology Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Pinnacle Biologics dépose une nouvelle indication pharmaceutique en Allemagne et en France
2. MediSapiens sapprête à fournir à Bayer HealthCare Pharmaceuticals une nouvelle application informatique en nuage pour analyser et visualiser les données génomiques multidimensionnelles
3. Chipscreen Biosciences Announces Achievement of Primary Endpoint in Chidamide Registrational Trial in China
4. Oramed Pharmaceuticals Appoints New Chief Operating Officer and VP of Business Development
5. MetaStat Appoints David Epstein, Ph.D. as Advisor to Lead Drug Discovery
6. Ambit Biosciences Appoints David Parkinson, M.D., to Board of Directors
7. CIVCO to Feature New trUpoint ARCH SRS/SRT System at the 2nd ESTRO Forum 2013
8. Lynn Kramer, MD, Appointed Chief Clinical Officer of Eisai Product Creation Systems
9. US Prescription Medical Food Company Appoints Board of International Advisors
10. PharmaPoint: Osteoporosis - US Drug Forecast and Market Analysis to 2022
11. PharmaPoint: Osteoporosis - India Drug Forecast and Market Analysis to 2022
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... , Sept. 30, 2014 The Eastern ... Both established medical-device providers as well as new medical-device ... region, while simultaneously looking at ways to reduce the ... Using distributors is one of the effective means to ... devices distribution market in Eastern European and provides profiles ...
(Date:9/30/2014)... New York , September 30, 2014 ... - Global Industry Analysis, Market Size, Share, Growth and ... is expected to be worth USD 20.8 billion in ... billion in 2017, growing at a CAGR of 7.3% ... fundamental elements needed for various health purposes, especially to ...
(Date:9/30/2014)... 30, 2014 In a recent ... Fluid) backflow of the Eldor spinal needle 25G, 103 ... hole pencil point spinal needles of the same gauge ... Spinal anesthesia is an excellent type of regional anesthesia ... Anesthesia, etc. It is estimated that 100 ...
Breaking Medicine Technology:Medical Technologies Distributor Profiles in Eastern Europe 2Medical Technologies Distributor Profiles in Eastern Europe 3Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 2Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 3Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 4
... Mich., Nov. 9 Thomson Reuters today ... leading clinical surveillance solution that enables hospitals to identify ... clinical quality and reduce total cost of treatment. , ... no additional cost. , CareFocus 2.0 contains ...
... Shire plc (LSE: SHP, Nasdaq: ... availability of INTUNIV (TM) (guanfacine) Extended Release ... of Attention-Deficit/Hyperactivity Disorder ( ADHD ) in children ... formulation of guanfacine, is the first and only nonscheduled alpha-2A ...
Cached Medicine Technology:Thomson Reuters Clinical Surveillance Solution Offers Powerful New Functionality to Improve Clinical Quality and Reduce Costs 2Thomson Reuters Clinical Surveillance Solution Offers Powerful New Functionality to Improve Clinical Quality and Reduce Costs 3Once-Daily INTUNIV(TM) (guanfacine) Extended Release Tablets Now Available in Pharmacies Nationwide 2Once-Daily INTUNIV(TM) (guanfacine) Extended Release Tablets Now Available in Pharmacies Nationwide 3Once-Daily INTUNIV(TM) (guanfacine) Extended Release Tablets Now Available in Pharmacies Nationwide 4Once-Daily INTUNIV(TM) (guanfacine) Extended Release Tablets Now Available in Pharmacies Nationwide 5Once-Daily INTUNIV(TM) (guanfacine) Extended Release Tablets Now Available in Pharmacies Nationwide 6Once-Daily INTUNIV(TM) (guanfacine) Extended Release Tablets Now Available in Pharmacies Nationwide 7
(Date:9/30/2014)... HealthDay Reporter MONDAY, Sept. 29, 2014 ... -- artificial valves, hip replacements, surgical mesh and the like ... after their approval by the U.S. Food and Drug Administration, ... prominent nonprofit groups and published online Sept. 29 in ... medical device testing on lax oversight by the FDA. ...
(Date:9/30/2014)... Houston, TX (PRWEB) September 30, 2014 ... have new a place to visit on the Internet. ... one of Houston’s most respected cosmetic surgeons, has launched ... public about the benefits of Botox Cosmetic ... http://www.botoxcosmetichouston.com . , According to the new website, ...
(Date:9/30/2014)... September 30, 2014 Neuromuscular and ... throughout the United States and worldwide. It is ... are diagnosed each year, adding to the more ... disease. Approximately 400,000 people in the US are ... Add to these statistics the 2.4 percent of ...
(Date:9/30/2014)... CA (PRWEB) September 30, 2014 ... now offering gum depigmentation treatments for dark gums. Dark ... can make people feel extremely self-conscious about their smiles. ... or dark gums. “I am one of the few ... and I have treated celebrities, business leaders, high-ranking officials ...
(Date:9/30/2014)... 30, 2014 (HealthDay News) -- Herceptin is the best ... HER2-positive and should remain the standard of care for ... a long-term clinical trial. HER2-positive breast cancers tend ... cancer, according to the Mayo Clinic. For the ... either Herceptin (trastuzumab) or Tykerb (lapatinib) in addition to ...
Breaking Medicine News(10 mins):Health News:Medical Implant Devices Skate Through Review Process, Studies Claim 2Health News:Medical Implant Devices Skate Through Review Process, Studies Claim 3Health News:Medical Implant Devices Skate Through Review Process, Studies Claim 4Health News:Dr. Paul Vitenas Launches New Website To Showcase The Benefits Of Botox Cosmetic 2Health News:Dr. Paul Vitenas Launches New Website To Showcase The Benefits Of Botox Cosmetic 3Health News:North American Seminars Introduces a New OT PT CME Course, Evidence Based Rehab Techniques for Parkinsons, Multiple Sclerosis and Peripheral Neuropathy 2Health News:North American Seminars Introduces a New OT PT CME Course, Evidence Based Rehab Techniques for Parkinsons, Multiple Sclerosis and Peripheral Neuropathy 3Health News:Gummy Smile Dentist, Dr. Alex Farnoosh, is Now Offering Gum Depigmentation for Dark Gums 2
... who take commonly prescribed drugs for osteoporosis known as bisphosphonates ... of certain kinds of fractures of their thigh bone, a ... hip fractures. And, since the overall risk of thigh bone ... risk for hip and other osteoporosis-related fractures should not stop ...
... Huggins HealthDay Reporter , TUESDAY, Feb. 22 (HealthDay ... looks good on a resume when you,re young, it may ... A new study finds that seniors who speak three, four ... memory than their peers. Most people already know the ...
... February 22, 2011 (BRONX, NY) In an ... at Albert Einstein College of Medicine of ... improve survival after life-threatening blood loss. Nanoparticles containing nitric ... where they helped maintain blood circulation and protect vital ...
... Feb. 22, 2011 Getting more exercise, spending time ... can be as effective as drugs or counseling in ... anxiety, according to a UC Irvine study. In ... human behavior, philosophy and anthropology, as well as adjunct ...
... Reporter , TUESDAY, Feb. 22 (HealthDay News) -- Men and ... of ischemic stroke, which typically occurs when blood flow to ... within blood vessels, a new Danish study contends. In ... triglyceride fats than it is for cholesterol, even though cholesterol ...
... LANSING, Mich. Want to keep your boss happy? Smile ... Smile like you mean it. A new study led ... who fake smile throughout the day worsen their mood and ... a result of cultivating positive thoughts such as a ...
Cached Medicine News:Health News:Study links long-term use of osteoporosis drugs to unusual fractures 2Health News:Speaking Several Languages Might Protect Memory 2Health News:Speaking Several Languages Might Protect Memory 3Health News:Nanoparticles increase survival after blood loss 2Health News:Therapeutic lifestyle changes as useful as drugs in improving mental health 2Health News:High Triglyceride Levels Linked to Increased Stroke Risk: Study 2Health News:High Triglyceride Levels Linked to Increased Stroke Risk: Study 3Health News:Study: For a better workday, smile like you mean it 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: